GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (NAS:ZVRA) » Definitions » Net Margin %

ZVRA (Zevra Therapeutics) Net Margin % : -296.76% (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Zevra Therapeutics's Net Income for the three months ended in Dec. 2024 was $-35.74 Mil. Zevra Therapeutics's Revenue for the three months ended in Dec. 2024 was $12.04 Mil. Therefore, Zevra Therapeutics's net margin for the quarter that ended in Dec. 2024 was -296.76%.

The historical rank and industry rank for Zevra Therapeutics's Net Margin % or its related term are showing as below:

ZVRA' s Net Margin % Range Over the Past 10 Years
Min: -446.85   Med: -179.35   Max: -29.86
Current: -446.85


ZVRA's Net Margin % is ranked worse than
67.07% of 1002 companies
in the Biotechnology industry
Industry Median: -132.42 vs ZVRA: -446.85

Zevra Therapeutics Net Margin % Historical Data

The historical data trend for Zevra Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics Net Margin % Chart

Zevra Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -96.03 -29.86 -263.48 -167.69 -446.85

Zevra Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -153.96 -485.31 -447.85 -899.19 -296.76

Competitive Comparison of Zevra Therapeutics's Net Margin %

For the Biotechnology subindustry, Zevra Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zevra Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's Net Margin % falls into.


;
;

Zevra Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Zevra Therapeutics's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-105.511/23.612
=-446.85 %

Zevra Therapeutics's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-35.739/12.043
=-296.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zevra Therapeutics  (NAS:ZVRA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Zevra Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zevra Therapeutics Business Description

Traded in Other Exchanges
Address
1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Executives
Neil F. Mcfarlane director, officer: President and CEO C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
R. Laduane Clifton officer: VP Fin & Corp Controller C/O KEMPHARM, INC., 1170 CELEBRATION BLVD., #103, CELEBRATION FL 34747
Joshua Schafer officer: CCO & EVP, Bus. Development SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Timothy J. Sangiovanni officer: VP, Corporate Controller C/O KEMPHARM, INC., 2500 CROSSPARK RD, STE E-126, CORALVILLE IA 52241
Watton Corey Michael director 22045 KAREN STREET, ELKHORN NE 68022
Thomas Anderson director 215 FIRST STREET, CAMBRIDGE MA 02142
John B Bode director C/O TRIBUNE PUBLISHING COMPANY, 202 W. FIRST STREET, LOS ANGELES CA 90012
Douglas W Calder director 324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Wendy L Dixon director
Tamara A Seymour director C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Matthew R Plooster director 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Richard W Pascoe director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Christopher Posner director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Travis C Mickle director, 10 percent owner, officer: President & CEO 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241